These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 37719697)

  • 1. Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review.
    Lopez-Lopez JP; Gonzalez AM; Lanza P; Lopez-Jaramillo P
    Vasc Health Risk Manag; 2023; 19():605-615. PubMed ID: 37719697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A polypill strategy to improve adherence: results from the FOCUS project.
    Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polypill-based strategy vs. usual care for secondary prevention of cardiovascular disease: a meta-analysis of randomized controlled trials.
    Rivera A; Campos B; Ceolin S; Godoi A; Castanha E; Campello Jorge CA; Cardoso R
    Eur J Prev Cardiol; 2023 Nov; 30(16):1828-1837. PubMed ID: 37490769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Polypill on Adherence and Cardiovascular Outcomes: A Comprehensive Systematic Review with Meta-Analysis.
    Salim H; Musmar B; Saifi M; Ayyad M; Ruzieh M; Azar J; Nazzal Z
    Curr Cardiol Rev; 2024; 20(2):61-71. PubMed ID: 38265377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease.
    Wood F; Salam A; Singh K; Day S; Jan S; Prabhakaran D; Rodgers A; Patel A; Thom S; Ward H
    BMJ Open; 2015 Sep; 5(9):e008018. PubMed ID: 26423850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
    Palmer MJ; Machiyama K; Woodd S; Gubijev A; Barnard S; Russell S; Perel P; Free C
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD012675. PubMed ID: 33769555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Roshandel G; Khoshnia M; Poustchi H; Hemming K; Kamangar F; Gharavi A; Ostovaneh MR; Nateghi A; Majed M; Navabakhsh B; Merat S; Pourshams A; Nalini M; Malekzadeh F; Sadeghi M; Mohammadifard N; Sarrafzadegan N; Naemi-Tabiei M; Fazel A; Brennan P; Etemadi A; Boffetta P; Thomas N; Marshall T; Cheng KK; Malekzadeh R
    Lancet; 2019 Aug; 394(10199):672-683. PubMed ID: 31448738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.
    Castellano JM; Sanz G; Fernandez Ortiz A; Garrido E; Bansilal S; Fuster V
    J Am Coll Cardiol; 2014 Aug; 64(6):613-21. PubMed ID: 25104532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials.
    Rao S; Jamal Siddiqi T; Khan MS; Michos ED; Navar AM; Wang TJ; Greene SJ; Prabhakaran D; Khera A; Pandey A
    Prog Cardiovasc Dis; 2022; 73():48-55. PubMed ID: 35114251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polypill Strategy in Secondary Cardiovascular Prevention.
    De la Rosa A; Arrington K; Desai R; Acharya PC
    Curr Cardiol Rep; 2024 May; 26(5):443-450. PubMed ID: 38557814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review.
    Jahangiri R; Rezapour A; Malekzadeh R; Olyaeemanesh A; Roshandel G; Motevalian SA
    PLoS One; 2022; 17(7):e0271908. PubMed ID: 35901100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
    Ostovaneh MR; Poustchi H; Hemming K; Marjani H; Pourshams A; Nateghi A; Majed M; Navabakhsh B; Khoshnia M; Jaafari E; Mohammadifard N; Malekzadeh F; Merat S; Sadeghi M; Naemi M; Etemadi A; Thomas GN; Sarrafzadegan N; Cheng KK; Marshall T; Malekzadeh R
    Eur J Prev Cardiol; 2015 Dec; 22(12):1609-17. PubMed ID: 25230980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The polypill in cardiovascular prevention: successful through simplification? : New study results on the benefit of the polypill strategy in primary and secondary prevention].
    Despang P; Schikora M; Doehner W
    Inn Med (Heidelb); 2023 Jun; 64(6):598-604. PubMed ID: 37227456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
    Palmer MJ; Barnard S; Perel P; Free C
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012675. PubMed ID: 29932455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
    Soliman EZ; Mendis S; Dissanayake WP; Somasundaram NP; Gunaratne PS; Jayasingne IK; Furberg CD
    Trials; 2011 Jan; 12():3. PubMed ID: 21205325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
    Bramlage P; Sims H; Minguet J; Ferrero C
    Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
    Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
    Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mobile phone text messaging to improve medication adherence in secondary prevention of cardiovascular disease.
    Adler AJ; Martin N; Mariani J; Tajer CD; Owolabi OO; Free C; Serrano NC; Casas JP; Perel P
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011851. PubMed ID: 28455948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.
    López-Jaramillo P; González-Gómez S; Zarate-Bernal D; Serrano A; Atuesta L; Clausen C; Castro-Valencia C; Camacho-Lopez P; Otero J
    Ther Adv Cardiovasc Dis; 2018 Jun; 12(6):169-174. PubMed ID: 29546816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
    Roy A; Naik N; Srinath Reddy K
    Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.